onartuzumab
mAbexperimental
Onartuzumab is a humanized monoclonal antibody designed for the treatment of advanced non-small-cell lung cancer. — Wikipedia
Clinical trial activity
17 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
13
Phase 3
5
Phase 4
0
Earliest trial started Aug 1, 2007 (NCT01068977)
Timeline
Indications
Mechanism of action
- Hepatocyte growth factor receptorANTAGONIST
MET antagonist
Binds to the extracellular domain of MET, preventing the binding of its ligand, hepatocyte growth factor (HGF).
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOnartuzumab ↗
- ChEMBLCHEMBL1743051 ↗
Also known as
- metmab
- metmab
- onartuzumab
- onartuzumab
- onartuzumab
- pro-143966
- pro-143996
- ro5490258
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02488330 | Phase 3 | Aug 27, 2015 | Roche |
| NCT02044601 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2014 | Genentech, University of Texas at Houston |
| NCT01974258 | Phase 1 | Feb 1, 2014 | Roche |
| NCT02031744 | Phase 3 | Jan 22, 2014 | Roche |
| NCT02031731 | Phase 1 | Jan 13, 2014 | Roche |
| NCT01887886 | Phase 3 | Dec 1, 2013 | Roche |
| NCT01897038 | Phase 1 | Sep 1, 2013 | Roche |
| NCT01662869 | Phase 3 | Nov 1, 2012 | Genentech, Roche |
| NCT01590719 | Phase 2 | Jul 1, 2012 | Genentech, Roche |
| NCT01632228 | Phase 2 | Jun 1, 2012 | Roche |
| NCT01496742 | Phase 2 | Apr 1, 2012 | Genentech |
| NCT01519804 | Phase 2 | Apr 1, 2012 | Genentech |
| NCT01456325 | Phase 3 | Jan 1, 2012 | Genentech, Roche |
| NCT01418222 | Phase 2 | Sep 14, 2011 | Genentech, SCRI Development Innovations |
| NCT01186991 | Phase 2 | Mar 1, 2011 | Genentech, Roche |
| NCT00854308 | Phase 2 | Apr 1, 2009 | Genentech |
| NCT01068977 | Phase 1 | Aug 1, 2007 | Genentech |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 11 | 9 | 3 | 2011 |
| Genentech | For profit | 10 | 7 | 3 | 2007 |
| SCRI Development Innovations | For profit | 1 | 0 | 1 | 2011 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2014 |
4 organizations
Page 1 / 1